Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

Jorge J. Castillo; Thomas Guerrero-Garcia; Francesco Baldini; Emmanuelle Tchernonog; Guillaume Cartron; Slavisa Ninkovic; Kate Cwynarski; Daan Dierickx; Thomas Tousseyn; Frederick Lansigan; Yevgeny Linnik; Renzo Mogollon; Jose Tomás Navarro; Adam J. Olszewski; John L. Reagan; Pasquale Fedele; Michael Gilbertson; George Grigoriadis; Michele Bibas

doi:10.1111/bjh.15156

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

Jorge J. Castillo, Thomas Guerrero-Garcia, Francesco Baldini, Emmanuelle Tchernonog, Guillaume Cartron, Slavisa Ninkovic, Kate Cwynarski, Daan Dierickx, Thomas Tousseyn, Frederick Lansigan, Yevgeny Linnik, Renzo Mogollon, Jose Tomás Navarro, Adam J. Olszewski, John L. Reagan, Pasquale Fedele, Michael Gilbertson, George Grigoriadis, Michele Bibas

Medicine Monash Health

Research output: Contribution to journal › Letter › Other › peer-review

67 Citations (Scopus)

Original language	English
Pages (from-to)	679-682
Number of pages	4
Journal	British Journal of Haematology
Volume	184
Issue number	4
DOIs	https://doi.org/10.1111/bjh.15156
Publication status	Published - 1 Feb 2019

Keywords

Bortezomib
Chemotherapy
Plasmablastic lymphoma
Survival

Access to Document

10.1111/bjh.15156

Cite this

Castillo, J. J., Guerrero-Garcia, T., Baldini, F., Tchernonog, E., Cartron, G., Ninkovic, S., Cwynarski, K., Dierickx, D., Tousseyn, T., Lansigan, F., Linnik, Y., Mogollon, R., Navarro, J. T., Olszewski, A. J., Reagan, J. L., Fedele, P., Gilbertson, M., Grigoriadis, G., & Bibas, M. (2019). Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. British Journal of Haematology, 184(4), 679-682. https://doi.org/10.1111/bjh.15156

@article{a5124ac9989340d5a92396d2c3999a98,

title = "Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma",

keywords = "Bortezomib, Chemotherapy, Plasmablastic lymphoma, Survival",

author = "Castillo, \{Jorge J.\} and Thomas Guerrero-Garcia and Francesco Baldini and Emmanuelle Tchernonog and Guillaume Cartron and Slavisa Ninkovic and Kate Cwynarski and Daan Dierickx and Thomas Tousseyn and Frederick Lansigan and Yevgeny Linnik and Renzo Mogollon and Navarro, \{Jose Tom{\'a}s\} and Olszewski, \{Adam J.\} and Reagan, \{John L.\} and Pasquale Fedele and Michael Gilbertson and George Grigoriadis and Michele Bibas",

year = "2019",

month = feb,

day = "1",

doi = "10.1111/bjh.15156",

language = "English",

volume = "184",

pages = "679--682",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

Castillo, JJ, Guerrero-Garcia, T, Baldini, F, Tchernonog, E, Cartron, G, Ninkovic, S, Cwynarski, K, Dierickx, D, Tousseyn, T, Lansigan, F, Linnik, Y, Mogollon, R, Navarro, JT, Olszewski, AJ, Reagan, JL, Fedele, P, Gilbertson, M, Grigoriadis, G & Bibas, M 2019, 'Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma', British Journal of Haematology, vol. 184, no. 4, pp. 679-682. https://doi.org/10.1111/bjh.15156

TY - JOUR

T1 - Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

AU - Castillo, Jorge J.

AU - Guerrero-Garcia, Thomas

AU - Baldini, Francesco

AU - Tchernonog, Emmanuelle

AU - Cartron, Guillaume

AU - Ninkovic, Slavisa

AU - Cwynarski, Kate

AU - Dierickx, Daan

AU - Tousseyn, Thomas

AU - Lansigan, Frederick

AU - Linnik, Yevgeny

AU - Mogollon, Renzo

AU - Navarro, Jose Tomás

AU - Olszewski, Adam J.

AU - Reagan, John L.

AU - Fedele, Pasquale

AU - Gilbertson, Michael

AU - Grigoriadis, George

AU - Bibas, Michele

PY - 2019/2/1

Y1 - 2019/2/1

KW - Bortezomib

KW - Chemotherapy

KW - Plasmablastic lymphoma

KW - Survival

UR - https://www.scopus.com/pages/publications/85043452838

U2 - 10.1111/bjh.15156

DO - 10.1111/bjh.15156

M3 - Letter

AN - SCOPUS:85043452838

SN - 0007-1048

VL - 184

SP - 679

EP - 682

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

Keywords

Access to Document

Other files and links

Cite this